Business Wire

Powering Precision Health Announces Inaugural European Summit in Amsterdam December 12-13, 2018

Jaa

Powering Precision Health (PPH), the first innovation-driven summit focused on precision health, today announced much-anticipated details for its 2018 summit, which will take place in Amsterdam Dec. 12-13.

Led by life sciences executive Kevin Hrusovsky, PPH is a non-profit organization made possible through the contributions of a wide range of sponsors committed to disrupting healthcare with innovations enabling safer, less invasive and more effective personalized drugs and treatments, as well as ultra-early detection technologies to identify diseases during their earliest, most treatable stages. The summit explores technologies and advances that can be used to identify and manage environmental disease triggers, catalyzing the promise for disease prevention and furthering strategies for slowing disease progression through lifestyle modifications and other techniques. The summit attracts renowned medical leaders, innovators, investors and advocates who are focused on advancing precision health.

“This is our first PPH summit to be held in Europe and will focus primarily on disruptive digital biomarker strategies for oncology and neurodegeneration,” said Kevin Hrusovsky, PPH Founder and Chairman. “The FDA has recently issued guidance on using biomarkers as surrogate endpoints for disease progression and is proactively utilizing fast-track approval processes for innovative diagnostics that transform medicine, particularly if they focus on high-priority diseases such as cancer and neurodegeneration. Blood-based digital biomarkers are unveiling a sea of new opportunities for seeing disease earlier, long before symptoms or when imaging is unable to detect it, opening up a vast opportunity to revolutionize new strategies for drug development, patient drug response monitoring and early detection.”

A new field of “on-therapy diagnostics” is emerging as a technique to rapidly determine if patients respond to drug therapies and treatments and if not, enabling quick intervention to alternative therapies. There is a mounting body of evidence from numerous medical innovators that digital biomarkers can play a disruptive role in most of these emerging approaches. At the summit, top thought leaders in the field of neurodegeneration will review data obtained with a highly sensitive serum Neurofilament light (NfL) assay as an early indicator of neuronal damage, with particularly compelling data on Multiple Sclerosis (MS) patients. Early information will also be shared about a major ground-breaking concussion study underway including football players at 21 major U.S. universities. In addition, top oncology thought leaders will explore similar digital biomarker techniques for measuring baseline movements of cytokines in blood, as an early indicator of efficacy or toxicity response.

A special breakout session will be held on the morning of Dec. 13 for NfL specifically, given the emerging importance of this biomarker, which could be relevant as a surrogate endpoint for 15 different MS drugs totaling more than $22B in sales each year, as well as 63 MS drug trials already underway. Quanterix’ ultrasensitive serum NfL assay, currently deployed in many drug trials and undergoing a major global analytical validation study with many pharmaceutical and biotechnology companies, will be reviewed during the breakout session.

Thanks to the incredible generosity of multiple sponsors, including Novartis, Quanterix, JP Morgan, Canaccord Genuity, Cowen Group, Leerink, Mintz Levin, and Avison Young, this year’s event is completely free to all participants. However, space is limited so an invitation must be requested here by anyone interested in attending. Learn more about the Powering Precision Health movement and the 2018 summit here.

“If you’re an innovator, investor or part of a patient advocacy group who cares about these diseases, you should be at PPH 2018,” continued Hrusovsky. “In fact, if you or anyone you know has been impacted by cancer, a concussion or neurodegenerative conditions like Alzheimer’s or MS, this should be a must-attend event for you!”

Hrusovsky’s opening keynote address will be recorded and available here for listening shortly after the conclusion of the summit.

About Powering Precision Health

Powering Precision Health is the world's first independent, non-profit organization dedicated to bringing the world's leading physicians, scientists, innovators, investors and patient advocates together to unveil their latest research on new biomarkers that are revolutionizing precision health. Founded by Kevin Hrusovsky, a widely acclaimed thought leader and visionary in life sciences and personalized medicine, Powering Precision Health is a movement that represents the intersection of new technological capabilities with the latest medical research. It’s rooted in the science of precision medicine, which shows personalized treatments to be an increasingly more effective way to maximize drug efficacy and minimize toxicity. In addition to the impact environmental and lifestyle factors can have on minimizing disease triggers, precision health marks an evolution in the way we approach disease and aims to inspire a full healthcare transformation, from philosophy to approach to outcome. In an industry often plagued by skepticism and marred by false promises, PPH puts science first and brings together stakeholders that span from fundamental research to clinical practice, investors, policy makers, patient advocacy groups, and anyone who embraces the vision of Powering Precision Health. Featuring a distinguished keynote lineup of dignitaries, the summit unveils groundbreaking approaches to prevention, early diagnosis, and next-generation treatments. Powering Precision Health is supported thanks to the generous contributions of sponsors from a wide range of companies and organizations committed to advancing precision health.

Twitter (@PPHSUMMIT): https://twitter.com/PPHSUMMIT

LinkedIn: https://www.linkedin.com/company/powering-precision-health/

Contact information

Lindsay Poole, 617-502-4300
Pan.quanterix@pancomm.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Secure-D Exposes Suspicious Android App with 500 Million Downloads22.5.2019 16:49:00 EESTTiedote

Upstream, a leading mobile technology company, has unveiled that the popular Android application VidMate triggers suspicious background activity. Hidden software within the app delivers invisible ads, generates fake clicks and purchases, installs other suspicious apps without consent and collects personal users’ information. Consequently, it depletes users’ data allowance and brings unwanted charges. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190522005501/en/ With over 500 million downloads reported, VidMate is a popular Android application for streaming and downloading videos and songs from services such as Dailymotion, Vimeo, and YouTube. It is not available in the Google Play Store but is distributed through third-party app stores like CNET or Uptodown. According to publicly available information, VidMate was developed by a subsidiary of UC Web, which is owned by Chinese conglomerate Alibaba. Over a recent period Upst

Airship’s Data Study Reveals the State of Global Mobile Permissions One Year into GDPR22.5.2019 16:35:00 EESTTiedote

With GDPR reaching its one year anniversary May 25, customer engagement company Airship today revealed top-level results of its global benchmark study, examining the state of mobile app user permissions across nearly 700 million people worldwide. While marketers trimmed customer lists to meet new regulatory requirements for "traditional" channels (i.e., email), mobile app audiences continue to grow — up globally by +16.6 percent year over year. Businesses are also sending more notifications — averaging 36 per user per month (up 18.4 percent since last year) — while the average notification opt-in rate remains high at over two-thirds (67 percent) of global app users. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190522005486/en/ With mobile app audiences growing around the world, businesses are more heavily leveraging notifications with negligible impact to opt-in rates. (Graphic: Business Wire) These metrics vary at a regio

Diligent Launches Modern Governance to Address Dangerous Governance Deficits and Announces New Modern Governance Summit22.5.2019 16:27:00 EESTTiedote

Today, Diligent Corporation launched a new category, called modern governance, designed to provide leaders with the missing key to bring governance into the digital age, along with new technology and a summit to support this well-designed system. Modern governance is the practice of empowering leaders with technology, insights, and processes to fuel good governance that organizations require to thrive and endure. Modern governance helps organizations address governance deficits. A governance deficit means an organization lacks the security, foresight, and accountability to withstand the onslaught of contemporary challenges – such as activist investors, cyber risk, regulation, diversity and global uncertainty. Feedback from Diligent’s 16,000 clients and the 600,000 leaders who use its technology – including more than 50% of the Fortune 1000, 70% of the FTSE 100, and 65% of the ASX – sparked the need for rethinking how companies and their boards should approach governance to navigate tod

Wipro Builds a Blockchain-Based Solution for Travacoin to Enable Digital Currency-Based Payments for the Airline Industry22.5.2019 15:19:00 EESTTiedote

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting, and business process services company, today announced that it has developed a blockchain-based payment solution for Travacoin, a company specializing in an eponymous digital payment solution. Travacoin is a digital payment system which enables airlines to refund and compensate passengers in a timely manner when a disruption occurs. Passengers will be notified of a delay or cancellation and refunded in this digital currency, which can be used to repurchase airline tickets, book hotels and avail other airport and travel related services. Passengers will benefit by way of a significant reduction in the waiting time for compensation. In addition, passengers can use Travacoins at retail stores in and around the airport and avail attractive discounts offered by retail partners. By compensating passengers with Travacoins, airlines will be able to reduce their administrative overheads and

New Fluid Dispensing Guide for Stock Lubrication and Metal Stamping from Nordson EFD22.5.2019 15:15:00 EESTTiedote

Nordson EFD , a Nordson company (NASDAQ: NDSN), the world’s leading precision fluid dispensing systems manufacturer, has released a new solutions guide for stock lubrication and metal stamping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190522005010/en/ The Stock Lubrication Solutions Guide is an overview of how Nordson EFD’s MicroCoat® lubrication system provides more consistent oil coverage and significantly reduces oil waste by up to 90%. By doing so the system quickly pays for itself by extending tool life and reducing oil usage, thus lowering waste disposal costs. In the guide, eight MicroCoat customers share application details that illustrate the benefits of the system’s Low Volume Low Pressure (LVLP) technology. Each customer has a different application with different problems to solve. “Our MicroCoat system is truly the first stock lubrication system to provide consistent oil coverage without overspray,” said Cl

Altasciences Leads Research on Chemical Nerve Agent Therapeutic from Preclinical to Clinical Phase I22.5.2019 15:04:00 EESTTiedote

Altasciences announced today that they have been selected by Leidos Health to guide and support the development of RAP-103 peptide as a chemical nerve agent therapeutic on behalf of the Medical CBRN Defense Consortium and funded by the Defense Threat Reduction Agency (DTRA). Altasciences will conduct the required Safety Testing, all IND-enabling studies (non-GLP and GLP), the necessary Phase I clinical trials, and associated bioanalytical analysis. “Altasciences’ preclinical and clinical teams are collaborating with Leidos Health on this important program. Together, we have developed a plan to move RAP-103 from preclinical, safely through early clinical trials. As a mid-size CRO specializing in a flexible, innovative approach to providing comprehensive early stage drug development, we have the experience and team in place to complete this program successfully, on time and within budget,” explained Steve Mason, Vice President, Site Operations, at Altasciences. For over 25 years, Altasci

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme